StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued to investors on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Cumberland Pharmaceuticals stock opened at $5.34 on Thursday. Cumberland Pharmaceuticals has a twelve month low of $1.04 and a twelve month high of $6.43. The firm has a 50 day moving average price of $2.36 and a 200-day moving average price of $1.66. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. The company had revenue of $9.09 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.